ZSTK474 Sensitizes Glioblastoma to Temozolomide by Blocking Homologous Recombination Repair
出版年份 2022 全文链接
标题
ZSTK474 Sensitizes Glioblastoma to Temozolomide by Blocking Homologous Recombination Repair
作者
关键词
-
出版物
Biomed Research International
Volume 2022, Issue -, Pages 1-17
出版商
Hindawi Limited
发表日期
2022-07-14
DOI
10.1155/2022/8568528
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Resveratrol sensitizes breast cancer to PARP inhibitor, talazoparib through dual inhibition of AKT and autophagy flux
- (2022) Ganesh Pai Bellare et al. BIOCHEMICAL PHARMACOLOGY
- The PI3K/mTOR Inhibitor Ompalisib Suppresses Nonhomologous End Joining and Sensitizes Cancer Cells to Radio- and Chemotherapy
- (2021) Jie Du et al. MOLECULAR CANCER RESEARCH
- BKM120 sensitizes glioblastoma to the PARP inhibitor rucaparib by suppressing homologous recombination repair
- (2021) Shaolu Zhang et al. Cell Death & Disease
- Hydroxychloroquine synergizes with the PI3K inhibitor BKM120 to exhibit antitumor efficacy independent of autophagy
- (2021) Xin Peng et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Palmitic acid inhibits prostate cancer cell proliferation and metastasis by suppressing the PI3K/Akt pathway
- (2021) Shan Zhu et al. LIFE SCIENCES
- Human Glioma Cells Acquire Temozolomide Resistance After Repeated Drug Exposure Via DNA Mismatch Repair Dysfunction
- (2020) KEI YAMASHIRO et al. ANTICANCER RESEARCH
- Dual PI3K/mTOR Inhibitor NVP-BEZ235 Enhances Radiosensitivity of Head and Neck Squamous Cell Carcinoma (HNSCC) Cell Lines Due to Suppressed Double-Strand Break (DSB) Repair by Non-Homologous End Joining
- (2020) Ulrike Schötz et al. Cancers
- Relationship among DNA double‐strand break (DSB), DSB repair, and transcription prevents genome instability and cancer
- (2020) Ayako Ui et al. CANCER SCIENCE
- Targeting the PI3K pathway and DNA damage response as a therapeutic strategy in ovarian cancer
- (2020) Tzu-Ting Huang et al. CANCER TREATMENT REVIEWS
- Targeting the DNA Damage Response to Overcome Cancer Drug Resistance in Glioblastoma
- (2020) Alessandra Ferri et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Discovery of novel PARP/PI3K dual inhibitors with high efficiency against BRCA-proficient triple negative breast cancer
- (2020) Junwei Wang et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Olaparib and α-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trial
- (2019) Panagiotis A Konstantinopoulos et al. LANCET ONCOLOGY
- LPCAT1 promotes brain metastasis of lung adenocarcinoma by up-regulating PI3K/AKT/MYC pathway
- (2019) Chunhua Wei et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- A Phase Ib/II, open-label, multicenter study of INC280 (capmatinib) alone and in combination with buparlisib (BKM120) in adult patients with recurrent glioblastoma
- (2019) Martin van den Bent et al. JOURNAL OF NEURO-ONCOLOGY
- Current Challenges and Opportunities in Treating Glioblastoma
- (2018) Andrea Shergalis et al. PHARMACOLOGICAL REVIEWS
- Potential Strategies Overcoming the Temozolomide Resistance for Glioblastoma
- (2018) Shabierjiang JIAPAER et al. NEUROLOGIA MEDICO-CHIRURGICA
- Recent advances in the use of PI3K inhibitors for glioblastoma multiforme: current preclinical and clinical development
- (2017) Hua-fu Zhao et al. Molecular Cancer
- ATM, ATR, and DNA-PK: The Trinity at the Heart of the DNA Damage Response
- (2017) Andrew N. Blackford et al. MOLECULAR CELL
- Class I phosphatidylinositol 3-kinase inhibitors for cancer therapy
- (2017) Wennan Zhao et al. Acta Pharmaceutica Sinica B
- Phase I dose escalation study of the PI3kinase pathway inhibitor BKM120 and the oral poly (ADP ribose) polymerase (PARP) inhibitor olaparib for the treatment of high grade serous ovarian and breast cancer
- (2016) U.A. Matulonis et al. ANNALS OF ONCOLOGY
- PI3K–mTOR Pathway Inhibition Exhibits Efficacy Against High-grade Glioma in Clinically Relevant Mouse Models
- (2016) Fan Lin et al. CLINICAL CANCER RESEARCH
- Phosphoinositide 3-kinase inhibitors induce DNA damage through nucleoside depletion
- (2016) Ashish Juvekar et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Stellettin B Induces G1 Arrest, Apoptosis and Autophagy in Human Non-small Cell Lung Cancer A549 Cells via Blocking PI3K/Akt/mTOR Pathway
- (2016) Ran Wang et al. Scientific Reports
- Mechanisms of ATM Activation
- (2015) Tanya T. Paull Annual Review of Biochemistry
- NVP-BEZ235, a novel dual PI3K–mTOR inhibitor displays anti-glioma activity and reduces chemoresistance to temozolomide in human glioma cells
- (2015) Zhiyun Yu et al. CANCER LETTERS
- Phase II study of PX-866 in recurrent glioblastoma
- (2015) M. W. Pitz et al. NEURO-ONCOLOGY
- The Dual PI3K/mTOR Inhibitor NVP-BEZ235 Is a Potent Inhibitor of ATM- and DNA-PKCs-Mediated DNA Damage Responses
- (2015) Bipasha Mukherjee et al. NEOPLASIA
- PI3K/Akt/mTOR pathway inhibitors enhance radiosensitivity in radioresistant prostate cancer cells through inducing apoptosis, reducing autophagy, suppressing NHEJ and HR repair pathways
- (2014) L Chang et al. Cell Death & Disease
- Glioblastoma and Other Malignant Gliomas
- (2013) Antonio Omuro JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Current clinical development of PI3K pathway inhibitors in glioblastoma
- (2012) P. Y. Wen et al. NEURO-ONCOLOGY
- PI3K Inhibition Impairs BRCA1/2 Expression and Sensitizes BRCA-Proficient Triple-Negative Breast Cancer to PARP Inhibition
- (2012) Yasir H. Ibrahim et al. Cancer Discovery
- Combining a PI3K Inhibitor with a PARP Inhibitor Provides an Effective Therapy for BRCA1-Related Breast Cancer
- (2012) Ashish Juvekar et al. Cancer Discovery
- MRE11 promotes AKT phosphorylation in direct response to DNA double-strand breaks
- (2011) Michael Fraser et al. CELL CYCLE
- Phase I, Dose-Escalation Study of BKM120, an Oral Pan-Class I PI3K Inhibitor, in Patients With Advanced Solid Tumors
- (2011) Johanna C. Bendell et al. JOURNAL OF CLINICAL ONCOLOGY
- ZSTK474, a novel phosphatidylinositol 3-kinase inhibitor identified using the JFCR39 drug discovery system
- (2010) De-xin Kong et al. ACTA PHARMACOLOGICA SINICA
- The Mechanism of Double-Strand DNA Break Repair by the Nonhomologous DNA End-Joining Pathway
- (2010) Michael R. Lieber Annual Review of Biochemistry
- Nuclear phosphoinositide 3-kinase controls double-strand break DNA repair
- (2010) A. Kumar et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Homologous recombination in DNA repair and DNA damage tolerance
- (2008) Xuan Li et al. CELL RESEARCH
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search